Progranulin and CTRP3 in Metabolic Syndrome

Metabolic Syndrome Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01668888
• Other study ID #: KoreaHealth_Progranulin
• Status: Completed
• Phase: N/A
• First received: August 14, 2012
• Last updated: August 16, 2012
• Start date: May 2012
• Est. completion date: August 2012

Study information

• Verified date: August 2012
• Source: Korea University
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Inflammation has been known to be a pivotal pathogenic mechanism of obesity-related disorders such as type 2 diabetes, metabolic syndrome and atherosclerosis. Adipose tissue functions as a major endocrine organ by adipokine mediated modulation of a number of signaling cascades in target tissues, that has pro-inflammatory or anti-inflammatory activities. Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to clarify the clinical meaning of these two adipokines in the subjects with or without metabolic syndrome

Recruitment information / eligibility

• Status: Completed
• Enrollment: 127
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• 20<age<80

• apparently healthy subjects

Exclusion Criteria:

• a history of CVD

• diabetes

• stage 2 hypertension

• malignancy

• severe renal or hepatic disease

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X

Locations

Country	Name	City	State
Korea, Republic of	Korea University Guro Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Korea University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum concentration of progranulin in the subjects with metabolic syndrome		12week	No
Primary	Serum concentration of CTRP3 in the subjects with metabolic syndrome		12week	No
Secondary	The relationship of serum progranulin levels with cardiovascular risk factors		12 week	No
Secondary	The relationship of serum CTRP3 levels with cardiovascular risk factors		12 week	No